Is Ivermectin Effective at Treating COVID-19?
Ivermectin can control viral replication within human beings.
A piece of antiviral research, published in June 2020, shows patients who were given five μM Ivermectin experienced a 5000-fold reduction in viral RNA (Ribonucleic Acid) in 48 hours. It also led to a 99.8% depletion in cell-associated RNA.
Ivermectin can reduce hospitalisation rates amongst COVID-19 patients.
A double-blind, placebo-controlled IVERCOR-COVID-19 trial was conducted among 501 patients in two groups. The group treated with Ivermectin had 5.6% of people requiring hospitalisation due to COVID-19, whereas the placebo group had 8.4% hospitalised subjects.
Ivermectin can kill the novel coronavirus within 48 hours.
Researchers from the Biomedicine Discovery Institute (BDI), at Monash University in Australia, have claimed that Ivermectin can kill the novel coronavirus within 48 hours. However, Dr Wagstaff, a part of the group, added that they would have to figure out the right dosage.
The fight against misinformation needs a hero like you.
Add your views to this topic by signing up. You’ll also be able to add or vote on sources, and start new topics. Because if you don’t fight misinformation, who will?
Ivermectin acts as an add-on treatment for COVID-19.
A total of four studies involving 629 RT-PCR COVID-positive patients were part of a systematic review. Out of these patients, 397 received Ivermectin alongside the standard treatment. The analyses show a significant fall in all-cause mortality among patients taking Ivermectin.
An FDA (Food and Drug Administration) letter suggests against using Ivermectin for humans.
A letter by the FDA expressed concern about the health of consumers self-medicating by taking Ivermectin, which is intended for animal usage. Ivermectin should only be used when prescribed by a licensed healthcare provider.
There is no scientific basis for a potential therapeutic effect of Ivermectin against COVID-19.
A statement released by Merck & Co. stated that their analysis showed that Stromectol (US name for Ivermectin) did not have any proven therapeutic effect against COVID-19, as concluded in their pre-clinical studies.
Ivermectin leads to lower mortality in hospitalised COVID-19 patients.
In a study conducted by ICON, which involved 280 patients, 173 received at least one dose of Ivermectin. After a careful analysis, it was found that the overall mortality amongst those given Ivermectin stood at 15%—significantly lower than other subjects in the study (25.2%).
WHO (World Health Organization) suggests clinical trials for gauging the effectiveness of Ivermectin against COVID-19 should be conducted.
A guideline development group assessed Ivermectin as a potential cure for COVID-19. This was based on COVID-related hospitalization, mortality, and need for ventilation. About 2407 patients underwent randomized controlled trials, but the results were insufficient.